知名药企突然被曝欠薪，有员工表示：离职流程没人推进，公司最新回应

Core Viewpoint - The article discusses the financial difficulties faced by Fangteng Pharmaceutical, a CRO company, due to salary delays and operational challenges, highlighting the broader issues within the CRO industry in China [3][4][12]. Company Overview - Fangteng Pharmaceutical was established in 2012 and has extensive experience in conducting over 1,000 Phase I to IV clinical trials across 25 therapeutic areas [3][6]. - The company was previously a subsidiary of Fang'en Pharmaceutical, which was rebranded as ClinChoice in 2020, and is set to become an independent entity from ClinChoice on January 29, 2024 [4][6][11]. Financial Issues - Since last year, Fangteng has made adjustments to its salary structure, leading to salary reductions and delays in wage payments, with employees reporting unpaid salaries for April and May [3][11]. - The company has faced claims that its financial difficulties stem from the freezing of accounts due to the transfer of 980 million yuan in receivables to its parent company [11]. Industry Context - The CRO industry in China has seen rapid growth since the 1990s, but recent years have brought significant challenges, including a decline in investment and an oversaturated market with increasing competition [6][13]. - The number of qualified clinical trial institutions in China has more than doubled from 625 in early 2018 to over 1,180 by 2022, leading to price reductions and increased competition among CROs [13][14]. Future Prospects - Despite current challenges, the CRO market in China is projected to grow significantly, with estimates suggesting it could reach $22.9 billion by 2025, up from $7.6 billion in 2020 [14]. - The article emphasizes the need for CRO companies, especially smaller ones, to focus on their core competencies and ensure sustainability in a challenging environment [14][15].